Global Humanized Mouse and Rat Model Market Forecast to 2022

Estimated reading time: 2 minutes

The humanized mouse models market is projected to reach $128.9 Million by 2022 from $80.3 Million in 2017, at a CAGR of 9.9% during the forecast period. The humanized rat models market is expected to reach $8.9 Million by 2022 from $5.9 Million in 2017, at a CAGR of 8.4% during the forecast period.

The key factors boosting market growth are increasing number of R&D activities in pharmaceutical and biotechnology companies, increasing number of research activities involving humanized models, continuous support in the form of investments and grants from the government and private sectors, and growing demand for personalized medicine.

By type, the humanized mouse models market is segmented into genetic and cell-based humanized mouse models. In 2017, the genetic models segment accounted for the largest share of the humanized mouse models market. The factors contributing to the large share of this segment include its widespread use in compound analysis and biological efficacy & safety testing.

Furthermore, the cell-based humanized mouse models is categorized into CD34, PBMC, and BLT humanized mouse models. In 2017, the CD34 models segment accounted for the largest share of the cell-based humanized mouse models market and is expected to register the highest growth rate during the forecast period.

The major factors driving the growth of this market are usage of CD34 mouse models in in-vivo platforms for analyzing the safety and effectiveness of potential new drugs that can modulate the immune system. They are used for long-term studies in the fields of immuno-oncology, infectious disease, and graft versus host disease. Thus, the growing application areas of CD34 models are expected to trigger the demand for these models in the coming years.

By application, the humanized mouse models market is segmented into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The oncology segment is estimated to grow at the highest CAGR owing to factors such as increasing research activities and growing funding from various governments to carry out research studies on cancer.

By end user, the humanized mouse models market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. The pharmaceutical & biotechnology companies segment accounted for the largest share of the humanized mouse models market in 2017. However, the contract research organizations (CROs) segment of the market is projected to grow at the highest CAGR during the forecast period. Increasing number of pharmaceutical companies outsourcing their preclinical studies to contract research organizations (CROs) is one of the factors contributing to the growth of this segment.